Journals / İstanbul Tıp Fakültesi Dergisi / 2006 / Cilt: 69 - Sayı: 1

Çocuklarda renal osteodistrofide oral pulse kalsitriol tedavisi

Oral pulse calcitrıoltherapy in children with renal osteodystrophy

Pages
5–9
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Materials and methods: After baseline determination of serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), urea, creatinine, intact parathyroid hormone (iPTH), osteocalcin, calcitriol levels and parathyroid gland ultrasonography, oral pulse calcitriol therapy was started at doses of 2 µg, three times a week, and all these parameters were followed up for a period of 4-6 months.Results: Serum iPTH levels measured in the 2nd and 6th months were significantly lower than basal serum iPTH levels (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to determine the effects and safety of oral pulse calcitriol therapy in patients with renal osteodystrophy (ROD) refractory to the conventional oral vitamin D therapy.
📊
Key Findings & Data:Objective: The aim of this study was to determine the effects and safety of oral pulse calcitriol therapy in patients with renal osteodystrophy (ROD) refractory to the conventional oral vitamin D therapy.
💡
Conclusion & Impact:Materials and methods: After baseline determination of serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), urea, creatinine, intact parathyroid hormone (iPTH), osteocalcin, calcitriol levels and parathyroid gland ultrasonography, oral pulse calcitriol therapy was started at doses of 2 µg, three times a week, and all these parameters were followed up for a period of 4-6 months.Results: Serum iPTH levels measured in the 2nd and 6th months were significantly lower than basal serum iPTH levels (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to determine the effects and safety of oral pulse calcitriol therapy in patients with renal osteodystrophy (ROD) refractory to the conventional oral vitamin D therapy. Materials and methods: After baseline determination of serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), urea, creatinine, intact parathyroid hormone (iPTH), osteocalcin, calcitriol levels and parathyroid gland ultrasonography, oral pulse calcitriol therapy was started at doses of 2 µg, three times a week, and all these parameters were followed up for a period of 4-6 months.Results: Serum iPTH levels measured in the 2nd and 6th months were significantly lower than basal serum iPTH levels (p

Özet

Amaç: Bu çalışmanın amacı, konvansiyonel oral D vitamini tedavisine dirençli renal osteodistrofili çocuklarda oral “pulse” kalsitriol tedavisinin etkinliğini değerlendirmekti. Gereç ve yöntem: Bazal serum kalsiyum, fosfor, alkalen fosfataz, üre, kreatinin, intakt paratiroid hormon (iPTH), osteokalsin, kalsitriol düzeyleri için örnek alındıktan ve paratiroid bezi ultrasonografisi yapıldıktan sonra haftada üç kez, 2 µg oral pulse kalsitrioil tedavisi başlandı ve tüm parametreler 4-6 ay süreyle izlendi.Bulgular: İkinci ve 6. ayda ölçülen serum iPTH düzeyleri bazal düzeye göre anlamlı olarak düştü (p

🔖

Cite This Article

GÜLBABA, G., NAYIR, A., EMRE, S., BİLGE, I., ŞİRİN, A., KARA, B. (2022). Çocuklarda renal osteodistrofide oral pulse kalsitriol tedavisi. İstanbul Tıp Fakültesi Dergisi, Cilt: 69 - Sayı: 1, 5–9. https://ajindex.com/articles/552719

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Bilge I, Emre S, Şirin A, Nayır A, Öktem F. Çocuk hemodiyaliz hastalarında dirençli sekonder hiperparatiroidizm tedavisinde intravenöz kalsitriol uygulaması. İst Tıp Fak Mecmuası 2000; 63:76-83
  2. Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A. Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 1995; 9:606-608
  3. Coizon BD, Salusky ID. Renal Osteodystrophy. In: Avner ED, Harmon WE, Niaudet P (eds). Pediatric Nephrology. Lippincott, Williams, Wilkins. Philadelphia, USA, 5th ed., 2004; pp 1347- 1373
  4. Dahl NV, Foote EF. Pulse oral calcitriol therapy for renal osteodystrophy. ANNAJ 1997; 25:550-555
  5. Delmez JA, Slatopolsky E. Recent advances in the pathogenesis and therapy of uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1991; 72:735-739
  6. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68:221-228
  7. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G. Low dose intravenous calcitriol treatment of secondary hyperparathyroidism in haemodialysis patients. Kidney Int 1992; 4:1191-1198
  8. Malberti F, Surian M, Cosci P. Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7:822-828
  9. Martinez ME, Selgas R, Miguel JL, Balaguer G, Cabezudo MJC. Osteocalcin levels in uremic patients. Nephron 1991; 59:429-433
  10. Moe SM. Renal osteodystrophy. In: Pereira BJG, Sayegh MH, Blake P (ed). Chronic Kidney Disease, Dialysis, Transplantation. Elsevier, Saunders. Philadelphia, USA, 2nd ed., 2005; pp 136- 157
  11. Muramoto H, Haruki K, Yoshimura A, Mimo N, Oda K, Tofuku Y. Treatment of refractory hyperparathyroidism in patients on haemodialysis by intermittent oral administration of 1,25 (OH)2 vitamin D3. Nephron 1991; 58:288-294
  12. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B. Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 1988; 34:840-844
  13. Quarles LD, Yohay YD, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA. Prospective trial of pulse oral versus intravenous calcitriol of hyperparathyroidism in ESRD. Kidney Int 1994; 45:1710-1721
  14. Slatopolsky